Although we have previously shown that 1–2 μM thioridazine requires DRD2 to inhibit self-renewal in basal-like breast cancer cell lines, thioridazine may block self-renewal through the inhibition of other receptors. The gene discussed is DRD2; the disease is breast carcinoma.